Opendata, web and dolomites

inhibitAUTO TERMINATED

Towards a New Frontier in Autophagy Inhibition: The Development of a Novel Class of ChemicalProbes and Identification of Their Associated Biological Target

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 inhibitAUTO project word cloud

Explore the words cloud of the inhibitAUTO project. It provides you a very rough idea of what is the project "inhibitAUTO" about.

reaction    host    linked    unknown    phenotypic    rationalised    sp3    provides    inhibitors    action    biophysical    mode    healthcare    probes    active    druggability    fellowship    systematic    potent    cross    chemical    vital    sp2    coupling    prepared    potency    modulates    scientific    biology    science    identification    investigations    class    cell    opportunity    protein    preparation    structure    biological    lab    collection    scaffold    autophagy    combines    academic    assays    inhibitory    independent    ambition    potentially    establishing    intrinsically    compound    compounds    synthetic    gt    discover    exploration    cancer    biomedical    engagement    researcher    chemistry    pioneering    technologies    proteins    variation    huge    selective    newest    improvement    classes    broad    dissect    autophagic    holistic    interrogate    significance    me    implications    quality    relationship    druggable    therapeutics    career    dysregulation    initiate    validation    newly   

Project "inhibitAUTO" data sheet

The following table provides information about the project.

Coordinator
MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN EV 

Organization address
address: HOFGARTENSTRASSE 8
city: MUENCHEN
postcode: 80539
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Germany [DE]
 Project website http://www.mpi-dortmund.mpg.de/institute/directors/herbert-waldmann
 Total cost 171˙460 €
 EC max contribution 171˙460 € (100%)
 Programme 1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
 Code Call H2020-MSCA-IF-2017
 Funding Scheme MSCA-IF-EF-ST
 Starting year 2018
 Duration (year-month-day) from 2018-03-01   to  2020-02-29

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN EV DE (MUENCHEN) coordinator 171˙460.00

Map

 Project objective

This action aims to discover a novel class of autophagy inhibitors and newly develop chemical probes that can identify their protein targets and dissect their biological mode of action. Autophagy dysregulation is intrinsically linked with major European healthcare challenges, including cancer. The identification of new classes of druggable autophagic proteins will have broad implications for the development of novel and more effective cancer therapeutics. To address the aims of this action, this proposal seeks support to initiate a pioneering and holistic chemical biology programme, which combines the newest technologies in synthetic chemistry and cell biology. Phenotypic investigations in the host lab recently identified new inhibitors of autophagy based on a novel scaffold, which modulates autophagy through an exciting but unknown pathway. In this action the use of a newly introduced sp2-sp3 cross-coupling reaction will allow systematic variation of the scaffold, exploration of its structure-activity relationship, and improvement of the potency of these inhibitors to facilitate the preparation of high-quality chemical probes. A focused compound collection (>100 compounds) will be prepared and investigated in cell-based assays, with the aim of establishing a broad, potent and selective class of inhibitors. The inhibitory mode of action will then be rationalised through identification, validation and engagement of the associated biological targets using further cell-based investigations and biophysical assays. Chemical probes will be generated from the most active inhibitors and used to identify and interrogate the druggability of a novel protein target with potentially huge significance for biomedical science. My ambition is to become an independent academic researcher in chemical biology at a leading European institution, and this Fellowship provides a vital opportunity for me to advance my scientific and career potential.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "INHIBITAUTO" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "INHIBITAUTO" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.2.)

PaSION (2018)

A longitudinal assessment of treatment experience, symptoms and potential associations with biomarkers in cancer patients undergoing immune checkpoint inhibitor therapy

Read More  

CoCoNat (2019)

Coordination in constrained and natural distributed systems

Read More  

EVOMET (2019)

The rise and fall of metastatic clones under immune attack

Read More